Oeffinger Kevin C, Fontham Elizabeth T H, Etzioni Ruth, Herzig Abbe, Michaelson James S, Shih Ya-Chen Tina, Walter Louise C, Church Timothy R, Flowers Christopher R, LaMonte Samuel J, Wolf Andrew M D, DeSantis Carol, Lortet-Tieulent Joannie, Andrews Kimberly, Manassaram-Baptiste Deana, Saslow Debbie, Smith Robert A, Brawley Otis W, Wender Richard
Memorial Sloan Kettering Cancer Center, New York, New York.
Louisiana State University School of Public Health, New Orleans.
JAMA. 2015 Oct 20;314(15):1599-614. doi: 10.1001/jama.2015.12783.
Breast cancer is a leading cause of premature mortality among US women. Early detection has been shown to be associated with reduced breast cancer morbidity and mortality.
To update the American Cancer Society (ACS) 2003 breast cancer screening guideline for women at average risk for breast cancer.
The ACS commissioned a systematic evidence review of the breast cancer screening literature to inform the update and a supplemental analysis of mammography registry data to address questions related to the screening interval. Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms.
Screening mammography in women aged 40 to 69 years is associated with a reduction in breast cancer deaths across a range of study designs, and inferential evidence supports breast cancer screening for women 70 years and older who are in good health. Estimates of the cumulative lifetime risk of false-positive examination results are greater if screening begins at younger ages because of the greater number of mammograms, as well as the higher recall rate in younger women. The quality of the evidence for overdiagnosis is not sufficient to estimate a lifetime risk with confidence. Analysis examining the screening interval demonstrates more favorable tumor characteristics when premenopausal women are screened annually vs biennially. Evidence does not support routine clinical breast examination as a screening method for women at average risk.
The ACS recommends that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years (strong recommendation). Women aged 45 to 54 years should be screened annually (qualified recommendation). Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation). Women should have the opportunity to begin annual screening between the ages of 40 and 44 years (qualified recommendation). Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer (qualified recommendation). The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age (qualified recommendation).
These updated ACS guidelines provide evidence-based recommendations for breast cancer screening for women at average risk of breast cancer. These recommendations should be considered by physicians and women in discussions about breast cancer screening.
乳腺癌是美国女性过早死亡的主要原因。早期检测已被证明与降低乳腺癌的发病率和死亡率相关。
更新美国癌症协会(ACS)2003年针对乳腺癌平均风险女性的乳腺癌筛查指南。
ACS委托对乳腺癌筛查文献进行系统的证据审查以为更新提供信息,并对乳房X线摄影登记数据进行补充分析以解决与筛查间隔相关的问题。建议的制定基于证据的质量以及关于利弊平衡的判断(纳入价值观和偏好)。
在40至69岁女性中进行的筛查性乳房X线摄影与一系列研究设计中乳腺癌死亡人数的减少相关,并且推断性证据支持对70岁及以上健康状况良好的女性进行乳腺癌筛查。如果筛查从较年轻的年龄开始,由于乳房X线摄影的次数更多以及年轻女性的召回率更高,假阳性检查结果的累积终生风险估计会更高。关于过度诊断的证据质量不足以自信地估计终生风险。检查筛查间隔的分析表明,绝经前女性每年进行筛查与每两年进行筛查相比,肿瘤特征更有利。证据不支持将常规临床乳房检查作为平均风险女性的筛查方法。
ACS建议乳腺癌平均风险女性应从45岁开始进行定期筛查性乳房X线摄影(强烈建议)。45至54岁的女性应每年进行筛查(有条件建议)。55岁及以上的女性应改为每两年进行一次筛查或有机会继续每年进行筛查(有条件建议)。女性应有机会在40至44岁之间开始每年进行筛查(有条件建议)。只要总体健康状况良好且预期寿命为10年或更长,女性就应继续进行筛查性乳房X线摄影(有条件建议)。ACS不建议对任何年龄的平均风险女性进行临床乳房检查以筛查乳腺癌(有条件建议)。
这些更新后的ACS指南为乳腺癌平均风险女性的乳腺癌筛查提供了基于证据的建议。医生和女性在讨论乳腺癌筛查时应考虑这些建议。